Acandis

Acandis operates in the medical-device and healthcare manufacturing categories, with a focused portfolio for neurovascular intervention and stroke care. Its products span flow diversion, stenting, balloon dilation, and catheter-based procedures: examples include the DERIVO Embolisation Device, ACCLINO and CREDO stents, NeuroSpeed PTA Balloon Catheter, and NeuroSlider Microcatheter. HEAL Technology Coating is described as a stent coating intended to reduce thrombosis and inflammation and support endothelial healing. This breadth across devices used in related endovascular procedures is a distinguishing feature of the described offering, rather than evidence of a broad general-purpose medical-device business. Acandis is privately held and its latest listed financing is a $52.0 million venture round from January 2025, led by Lauxera Capital Partners. Its positioning is best understood as a specialized European neurovascular-device manufacturer with products addressing both ischemic and hemorrhagic stroke-related care needs.

Acandis’s growth profile combines a substantial financing event with an established, specialized product portfolio, but the available indicators do not establish a measured revenue or headcount growth rate. The clearest inflection point is the €50 million venture round announced on Jan 22, 2025, equivalent to about $52.0 million, with Lauxera Capital Partners as lead investor. The company’s employee range is listed as 101–250, while its hiring notice invites applications across R&D, production, sales, and administration; this suggests hiring interest across both technical and operational functions, without specifying open-role counts or hiring targets. Product activity in 2024 highlighted offerings including the Accero®-Rex-Stent and CARESTO® heal, while the broader portfolio includes flow diverters, stents, balloon catheters, and microcatheters. The historical 2022 three-year Mentice agreement added clinical-support software solutions to the company’s commercial relationships. Acandis’s July 2025 investment in Biograil represents a separate investment activity, not an additional Acandis funding round. Overall, the evidence points to continued investment in its neurovascular business, but product launches, employee-growth history, and financial performance are not sufficiently detailed to quantify the pace of expansion.